Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.

Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F.

Ann Oncol. 2015 Oct;26(10):2044-56. doi: 10.1093/annonc/mdv267. Review.

PMID:
26101426
2.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015.

PMID:
24837187
3.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026.

PMID:
24200698
4.

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN.

Clin Cancer Res. 2015 May 15;21(10):2315-24. doi: 10.1158/1078-0432.CCR-14-2666.

5.

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.

van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CM, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur Urol. 2015 Jun;67(6):981-5. doi: 10.1016/j.eururo.2014.11.033.

PMID:
25484141
6.

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN.

JAMA Oncol. 2016 Dec 1;2(12):1598-1606. doi: 10.1001/jamaoncol.2016.0494.

PMID:
27148695
7.

Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.

Modena A, Ciccarese C, Fantinel E, Bimbatti D, Tortora G, Massari F.

Expert Rev Anticancer Ther. 2015;15(9):1037-48. doi: 10.1586/14737140.2015.1063423. Review.

PMID:
26134919
8.

Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?

Oudard S, Angelergues A.

Nat Rev Urol. 2014 Jul;11(7):370-2. doi: 10.1038/nrurol.2014.144.

PMID:
24960604
9.

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.

Cancer Treat Rev. 2014 Feb;40(1):170-7. doi: 10.1016/j.ctrv.2013.06.008. Review.

10.

Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.

Hotte SJ.

Future Oncol. 2017 Feb;13(4):369-379. doi: 10.2217/fon-2016-0279. Review.

PMID:
27712093
11.

Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.

Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P.

Scand J Urol. 2014 Jun;48(3):268-75. doi: 10.3109/21681805.2013.860189.

PMID:
24255983
12.

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.

Eur Urol. 2015 Jan;67(1):23-9. doi: 10.1016/j.eururo.2014.06.045.

PMID:
25018038
13.

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.

van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS)..

Eur J Cancer. 2015 Nov;51(17):2562-9. doi: 10.1016/j.ejca.2015.07.037.

PMID:
26278646
14.

Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.

Quintela ML, Mateos LL, Estévez SV, Calvo OF, Herranz UA, Afonso FJ, Santomé L, Aparicio LA.

Cancer Treat Rev. 2015 Mar;41(3):247-53. doi: 10.1016/j.ctrv.2014.12.006. Review.

PMID:
25638257
15.

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.

Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV.

Cancer Treat Rev. 2015 Dec;41(10):884-92. doi: 10.1016/j.ctrv.2015.08.002. Review.

PMID:
26342718
16.

Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.

Chism DD, De Silva D, Whang YE.

Expert Rev Anticancer Ther. 2014 Nov;14(11):1369-78. doi: 10.1586/14737140.2014.928594. Review.

17.

Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.

Davies RS, Smith C, Lester JF.

Anticancer Res. 2016 Apr;36(4):1799-803.

PMID:
27069162
18.
19.

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.

Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K.

Eur J Cancer. 2015 Sep;51(14):1946-52. doi: 10.1016/j.ejca.2015.06.128.

PMID:
26208462
20.

Therapy Update for Metastatic Castration-Resistant Prostate Cancer.

Dinh JA, Baker D, Chahal M.

Consult Pharm. 2016;31(10):581-592. Review.

PMID:
27725068
Items per page

Supplemental Content

Support Center